NIH Forward-Funded $2.2 Billion in Multiyear Grants Last Year. Why That Math Is Crowding Out New Awards in FY26 — and What Investigators Should Do About It.

A quiet shift in how the National Institutes of Health distributes extramural research dollars is producing the largest single-year contraction in available funding for new grant applications since the 2013 sequester. NIH has accelerated its use of "multiyear funding" — obligating the full multi-year cost of a grant in a single fiscal year rather than spreading obligations across the years of the award — to a degree that is now visibly compressing the dollars available to fund new awards out of the FY2026 budget. The compression is documented in NIH's own grant obligation data, has been flagged by the Association of American Medical Colleges and the Association of American Universities, and has triggered a Congressional response that caps FY2026 multiyear obligations at prior-year levels.

The numbers tell the story unambiguously. In FY2024, the last full year before the current administration, NIH obligated $960 million across 1,067 multiyear-funded grants. In FY2025, that figure roughly doubled to $2.2 billion across more than 2,000 grants — about six percent of all NIH extramural obligations. In FY2026 through mid-May, NIH has already obligated $402 million across 601 multiyear grants. The comparable mid-May FY2025 figure was $79 million across 162 grants. The 2026 pace is, in other words, approximately five times the equivalent 2025 pace as measured at the same point in the fiscal year.

Heather Pierce, senior director for science policy and regulatory counsel at the Association of American Medical Colleges, captured the dynamic in a simple analogy in late May. "If you have $400,000 and you can fund one project for four years or four projects at $100,000 each for one year, the multiyear approach decreases precipitously the number of grants you can fund and the number of new ideas that happen." Lizbet Boroughs of the Association of American Universities added that the downstream effect is already visible at the institutional level: universities are "not accepting as many Ph.D. students" as a direct consequence of contracted research budgets, producing what she described as the predictable next-stage effect of "fewer trained scientists."

Why Multiyear Funding Is a Crowding-Out Mechanism

Federal grant accounting is more consequential than it appears. Most NIH research grants are structured as multi-year commitments — typically four or five years for R01s, the workhorse research project grant mechanism — but obligations are normally booked one year at a time. A four-year R01 awarded in FY2025 obligates the FY2025 budget for the first year only. Years two through four are obligated against future-year budgets when those fiscal years arrive. This pay-as-you-go structure allows NIH to fund a relatively predictable number of new grants each year because most of any given year's budget goes to new awards plus the next-year installments of previously-awarded grants.

Multiyear funding breaks that arithmetic. When NIH obligates the full multi-year cost of a grant in a single fiscal year — a $2 million four-year grant booked as $2 million against FY2026 rather than $500,000 against FY2026 and $500,000 each against FY2027, FY2028, and FY2029 — the current-year obligation consumes funding that would otherwise have been available to make additional new awards. The mechanism is not creating new research dollars. It is concentrating existing dollars onto fewer grants. The math is exact: every additional dollar obligated as forward-funding in FY2026 is a dollar not available to fund a new application in FY2026.

NIH program officials have publicly framed multiyear funding as a mechanism to provide funding stability to selected researchers and to reduce the administrative burden of annual progress reporting. There is genuine merit in that framing for high-confidence projects. The structural problem is one of scale: at a few hundred grants per year, forward-funding is a portfolio management tool. At more than 2,000 grants per year — six percent of all extramural obligations — it becomes a budget-compression mechanism that visibly constrains the pool available for new awards. The institutional response from research universities has reflected exactly that read: not opposition to the underlying tool, but concern about the rate at which it is being used.

The Congressional Cap and What It Does (and Doesn't) Fix

Congress responded to the documented FY2025 spike by capping FY2026 multiyear obligations at prior-year levels. The cap is a meaningful guardrail. It prevents the trend line from accelerating further than it already has. But it does not reverse the underlying compression. The FY2025 baseline is itself elevated relative to historical norms — more than double the FY2024 level — and the cap permits NIH to continue forward-funding at that elevated level through FY2026. The first-half FY2026 obligation data showing $402 million already booked indicates that NIH is on track to exhaust the prior-year-equivalent cap relatively early in the fiscal year if the pace continues.

The practical consequence for investigators is that the dollars available for new R01, R21, R03, K, U, and other extramural awards in the back half of FY2026 are likely to be substantially constrained relative to historical patterns. Payline contraction is the predictable manifestation. Several institutes have already signaled informally to grants management offices that their paylines will be tighter than originally projected, with the gap concentrated in the back half of the fiscal year. Applications submitted on the May, June, July, and August submission cycles will be reviewed against budget conditions that look meaningfully different from the conditions assumed at the start of the fiscal year.

The Congressional cap also does not address the corresponding structural question of which categories of research are being forward-funded versus which categories are being held to standard year-by-year obligation. NIH has not publicly disclosed the institute-by-institute or mechanism-by-mechanism distribution of FY2025 and early-FY2026 forward-funded grants. Investigators in fields that have benefited disproportionately from multiyear awards are seeing their fields well-funded for the next four years. Investigators in fields that have not benefited disproportionately are facing a constrained competition for new awards with no offsetting forward-funding benefit. The opacity of the institute-level distribution is itself a strategic problem for investigators trying to model their funding prospects.

What Investigators Should Do

The strategic implications for investigators planning submissions over the next 12 months are concrete and several.

Model the back-half-of-FY26 payline conservatively. Investigators with R01 applications scheduled for the June 5 / October 5 / February 5 cycle should assume meaningfully tighter paylines than the start-of-fiscal-year guidance suggested. Modify resubmission and competing-renewal strategy accordingly. Applications that would have scored comfortably above payline in FY2024 conditions may not score above the FY2026 back-half payline. This is the year to over-invest in revision quality.

Diversify funding sources more aggressively than usual. Investigators whose research programs depend heavily on annual NIH renewal should accelerate plans to apply to alternative funders — DARPA, ARPA-H, NSF, foundation funders aligned with the research domain, and disease-foundation partnerships. The compression in NIH availability does not extend uniformly across other agencies, and the institutional cost of diversification is substantially lower than the cost of a year-long funding gap.

Negotiate bridge funding at the institutional level early. Boroughs's observation that smaller institutions cannot provide bridge funding during transitions is empirically correct. Investigators at well-resourced research universities should engage their department chairs and deans about bridge mechanisms now — not when a renewal lapses. The 2026 funding environment will produce more renewal gaps than the historical baseline, and institutions with bridge mechanisms set up in advance will retain their faculty research programs through the gap. Institutions that scramble to set up ad-hoc bridges as gaps occur will lose researchers.

Reduce the headcount footprint of new applications where possible. The crowding-out math affects budget approval as much as it affects scoring. Modular budgets at the standard $250,000-per-year ceiling will face fewer second-guesses than budgets that exceed the modular threshold. Applications that propose larger budgets should justify them precisely against the science, not against historical institutional patterns.

Apply to the forward-funded tier intentionally where eligible. Multiyear-funded grants are not randomly distributed across applications. They are concentrated in mechanisms and programs that NIH leadership has prioritized for funding stability. Investigators whose research aligns with those priorities can apply specifically into mechanisms with high forward-funding rates and benefit from the trend rather than being penalized by it. Examples include certain center grants (P30, P50), program project grants (P01), and specific institute-priority RFAs. The strategic posture of "apply where the forward-funding is" is now a meaningful piece of NIH strategy in a way it was not two years ago.

The Larger Question

The forward-funding pattern is one of several structural changes reshaping how federal research dollars reach investigators in 2026. The OMB rewrite of 2 CFR Part 200 (the Uniform Guidance overhaul) is changing the administrative posture of every active grant. The Congressional appropriations process is producing tighter top-level budgets at most science agencies. The multiyear funding compression at NIH is producing tighter paylines at the agency level within whatever top-level budget Congress ultimately enacts.

The net effect on the research community is a year in which the difference between successful and unsuccessful grant applications will turn more on strategic positioning — submission timing, mechanism selection, partner identification, budget discipline — than on raw scientific merit. Strong science continues to be a necessary condition for funding. It is no longer a sufficient one. Investigators who treat the 2026 funding environment as a normal year, and submit on autopilot, will find their hit rates substantially lower than their FY2024 baselines suggested they should expect. Investigators who treat 2026 as the structurally unusual year it actually is, and plan accordingly, will preserve their research programs through the compression.

The Congressional cap on FY2026 forward-funding is a meaningful first step. It is not, by itself, sufficient to restore historical payline conditions. Investigators planning their work for the next 12 to 18 months should plan against the compressed conditions, not against the historical baseline that no longer applies.